132 related articles for article (PubMed ID: 38893023)
1. Drug Use Patterns in Myasthenia Gravis: A Real-World Population-Based Cohort Study in Italy.
Finocchietti M; Crescioli G; Paoletti O; Brunori P; Sciancalepore F; Tuccori M; Addis A; Vannacci A; Lombardi N; Kirchmayer U; The Caesar Study Group
J Clin Med; 2024 Jun; 13(11):. PubMed ID: 38893023
[No Abstract] [Full Text] [Related]
2. Potentially inappropriate drug use in myasthenia gravis: a real-world population-based cohort study in Italy.
Crescioli G; Finocchietti M; Paoletti O; Brunori P; Sciancalepore F; Tuccori M; Addis A; Vannacci A; Lombardi N; Kirchmayer U;
Front Neurol; 2023; 14():1293626. PubMed ID: 38178892
[TBL] [Abstract][Full Text] [Related]
3. Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy.
Antonini G; Habetswallner F; Inghilleri M; Mantegazza R; Rodolico C; Saccà F; Sgarzi M; deRuyck F; Paci S; Phillips G; Crippa L; Veronesi C; Perrone V; Degli Esposti L;
Heliyon; 2023 Jun; 9(6):e16367. PubMed ID: 37274644
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.
Narayanaswami P; Sanders DB; Thomas L; Thibault D; Blevins J; Desai R; Krueger A; Bibeau K; Liu B; Guptill JT;
Lancet Neurol; 2024 Mar; 23(3):267-276. PubMed ID: 38365379
[TBL] [Abstract][Full Text] [Related]
5. Adherence to riluzole therapy in patients with amyotrophic lateral sclerosis in three Italian regions-The CAESAR study.
Giometto S; Finocchietti M; Paoletti O; Lombardi N; Celani MG; Sciancalepore F; Lucenteforte E; Kirchmayer U;
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5736. PubMed ID: 38014926
[TBL] [Abstract][Full Text] [Related]
6. Plasma exchange for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2002; 2002(4):CD002275. PubMed ID: 12519572
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of myasthenia gravis in France: A retrospective claims database study (STAMINA).
Salort-Campana E; Laforet P; de Pouvourville G; Crochard A; Chollet G; Nevoret C; Emery C; Bouée S; Tard C
Rev Neurol (Paris); 2024 Mar; 180(3):202-210. PubMed ID: 37945494
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
10. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Kupersmith MJ; Latkany R; Homel P
Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and prognosis of myasthenia gravis in older people.
Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
J Am Geriatr Soc; 2000 Nov; 48(11):1442-8. PubMed ID: 11083321
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany.
Mevius A; Jöres L; Biskup J; Heidbrede T; Mahic M; Wilke T; Maywald U; Lehnerer S; Meisel A
Neuromuscul Disord; 2023 Apr; 33(4):324-333. PubMed ID: 36921445
[TBL] [Abstract][Full Text] [Related]
13. Myasthenia gravis: subgroup classification and therapeutic strategies.
Gilhus NE; Verschuuren JJ
Lancet Neurol; 2015 Oct; 14(10):1023-36. PubMed ID: 26376969
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroids for myasthenia gravis.
Schneider-Gold C; Gajdos P; Toyka KV; Hohlfeld RR
Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD002828. PubMed ID: 15846640
[TBL] [Abstract][Full Text] [Related]
15. Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
Sommer N; Sigg B; Melms A; Weller M; Schepelmann K; Herzau V; Dichgans J
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):156-62. PubMed ID: 9048716
[TBL] [Abstract][Full Text] [Related]
16. Maintenance IVIg therapy in myasthenia gravis does not affect disease activity.
Hellmann MA; Mosberg-Galili R; Lotan I; Steiner I
J Neurol Sci; 2014 Mar; 338(1-2):39-42. PubMed ID: 24267740
[TBL] [Abstract][Full Text] [Related]
17. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
18. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.
Brauner S; Eriksson-Dufva A; Hietala MA; Frisell T; Press R; Piehl F
JAMA Neurol; 2020 Aug; 77(8):974-981. PubMed ID: 32364568
[TBL] [Abstract][Full Text] [Related]
19. Management of Juvenile Myasthenia Gravis.
O'Connell K; Ramdas S; Palace J
Front Neurol; 2020; 11():743. PubMed ID: 32793107
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
